DALLAS, Dec. 8, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/ALTH
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Allos Therapeutics Inc. (ALTH) is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) an antifolate, is in phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, which is in a phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma.
In the report, the analyst notes:
"Since its inception in 1992, ALTH has not generated any revenue from product sales and has experienced significant net losses and negative cash flows from operations. ALTH has incurred these losses principally from costs incurred in its research and development programs, clinical manufacturing and from marketing, general and administrative expenses. On September 24, 2009, ALTH obtained accelerated approval from the FDA for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory PTCL. The Company began making FOLOTYN available for commercial sale in the United States on October 5, 2009, with an anticipated commercial launch in January 2010. ALTH's ability to generate revenue and achieve profitability is dependent on its ability, alone or with partners, to successfully commercialize FOLOTYN for the treatment of patients with relapsed or refractory PTCL.
"ALTH recently reported a new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN(TM) (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. The analysis evaluated the outcomes of patients who received a stem-cell transplant (SCT) before or after treatment with FOLOTYN."
To read the entire report visit: http://www.stockpreacher.com/n/ALTH
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.